MALVERN, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the appointment of C. Glenn Begley, PhD, F.R.A.C.P., F.R.C.P.A., F.R.C.Path., as senior vice president of research and development.
Dr. Begley, who was previously the vice president and global head of hematology and oncology research at Amgen, joins TetraLogic with over 30 years of clinical experience in medical oncology and hematology and in leading the strategy and coordination of oncology research. At TetraLogic, Dr. Begley will lead research and development and oversee translational studies to support birinapant, the lead Smac mimetic drug candidate in Phase 2 clinical development.
Dr. Begley has held several academic positions and his research has focused on translational clinical trials and regulation of hematopoietic cells. His early studies first described human G-CSF, and in later clinical studies, he first demonstrated that G-CSF-"mobilized" blood stem cells hastened hematopoietic recovery compared with bone marrow transplantation. This finding revolutionized the approach to hematopoietic cell transplantation. He also performed the earliest clinical studies with thrombopoietin. His basic research focused on hematopoietic regulation. He defined the function of the CSFs and their receptors. He was the first to molecularly clone the transcription factor SCL, and demonstrated its critical role in leukemia and normal hematopoiesis. Dr. Begley is Board Certified in Australia as a Medical Oncologist and Hematologist (F.R.A.C.P.), and Laboratory Hematologist (F.R.C.P.A., Australia; F.R.C.Path., United Kingdom) and has a PhD in cellular and molecular biology. He has published over 200 scientific papers and was elected to the prestigious Association of American Physicians in 2008.
About Birinapant
Birinapant (formerly TL32711) is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple Inhibitor of Apoptosis Proteins (IAPs). Birinapant has entered Phase 2 clinical development for various solid tumors and a Phase 1/2 study in acute myeloid leukemia (AML) is ongoing. In the clinical studies to date, birinapant has been well tolerated and exhibited rapid suppression of IAPs and antitumor activity.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial derived activator of caspases) for the treatment of cancers. The company’s institutional investors include Clarus Ventures, HealthCare Ventures, Quaker Partners, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company’s Web site at www.tetralogicpharma.com.